Nawal Ouzren, Sensorion CEO
Tiny biotech hammered as lead drug fails a key PhII study
Sensorion saw its shares collapse on Monday when the tiny French biotech reported that its only clinical-stage drug had failed the primary endpoint on a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
